Objective—dl-Nebivolol, a selective β1-adrenergic receptor antagonist, besides its
hypotensive activity exerts vasodilatory and platelet inhibitory effects in vitro by a mechanism …

Background Third generation β-adrenolytics, such as selective β1 adrenoceptor antagonist
nebivolol and non-selective β1/β2 and α1 adrenoceptor antagonist carvedilol, display …

Background—Nebivolol is a β1-selective adrenergic receptor antagonist with proposed nitric
oxide (NO)–mediated vasodilating properties in humans. In this study, we explored whether …

Nebivolol is a new and selective β 1‐adrenergic receptor antagonist whose haemodynamic
profile is different from that of classical β‐blockers. The blood pressure lowering effects of …

Background—Platelet activation is a feature of many cardiovascular diseases characterized
by endothelial dysfunction. The mechanistic relationship between impaired systemic nitric …

Nitric oxide (NO) is released by the endothelium preventing platelet adhesion to the vessel
wall. When released by platelets, NO inhibits further recruitment of platelets to a growing …

Nitric oxide (NO) exerts important vasodilatory, antiplatelet, antioxidant, antiadhesive, and
antiproliferative effects. Although endothelium derived NO has been shown to be of prime …

Nitric oxide (NO) is a powerful vasodilator and an inhibitor of platelet aggregation in vitro.
While the ability of NO to modulate vascular tone in vivo has been proven, only a few studies …

Nitric oxide (NO) was originally discovered as a vasodilator product of the endothelium. Over
the last 15 years, this vascular mediator has been shown to have important antiplatelet …

β-blockers are among the most widely used drugs in the prevention and treatment of
cardiovascular disease, although they are associated with increased peripheral resistance …